Treatment of COVID-19-Related Olfactory Disorder Promoted by Kakkontokasenkyushin'i: A Case Series
- PMID: 34108344
- DOI: 10.1620/tjem.254.71
Treatment of COVID-19-Related Olfactory Disorder Promoted by Kakkontokasenkyushin'i: A Case Series
Abstract
Olfactory disorders are one of the characteristic symptoms of the coronavirus disease of 2019 (COVID-19), which causes infection and inflammation of the upper and lower respiratory tract. To our knowledge, there are no treatments for COVID-19-related olfactory disorder. Here, we report five olfactory disorder cases in COVID-19, treated using the Japanese traditional (Kampo) medicine, kakkontokasenkyushin'i. We treated five patients with mild COVID-19 at an isolation facility using Kampo medicine, depending on their symptoms. Patients with the olfactory disorder presented with a blocked nose, nasal discharge or taste impairment. Physical examination using Kampo medicine showed similar findings, such as a red tongue with red spots and sublingual vein congestion, which presented as blood stasis and inflammation; thus, we prescribed the Kampo medicine, kakkontokasenkyushin'i. After administration, the numeric rating scale scores of the smell impairment improved within 3 days from 9 to 3 in case 1, from 10 to 0 in case 2, from 9 to 0 in case 3, from 5 to 0 in case 4, and from 9 to 0 within 5 days in case 5. Following the treatment, other common cold symptoms were also alleviated. Kakkontokasenkyushin'i can be used for treating nasal congestion, rhinitis, and inflammation in the nasal mucosa. The olfactory disorder in COVID-19 has been reportedly associated with inflammation and congestion, especially in the olfactory bulb and olfactory cleft. Kakkontokasenkyushin'i may be one of the treatment alternatives for the olfactory disorder with rhinitis in patients with COVID-19.
Keywords: Kampo medicine; blocked nose; coronavirus disease; kakkontokasenkyushin’i; olfactory disorder.
Similar articles
-
A multi-center, randomized controlled trial by the Integrative Management in Japan for Epidemic Disease (IMJEDI study-RCT) on the use of Kampo medicine, kakkonto with shosaikotokakikyosekko, in mild-to-moderate COVID-19 patients for symptomatic relief and prevention of severe stage: a structured summary of a study protocol for a randomized controlled trial.Trials. 2020 Oct 2;21(1):827. doi: 10.1186/s13063-020-04746-9. Trials. 2020. PMID: 33008479 Free PMC article.
-
A structured summary of a study protocol for a multi-center, randomized controlled trial (RCT) of COVID-19 prevention with Kampo medicines (Integrative Management in Japan for Epidemic Disease by prophylactic study: IMJEDI P1 study).Trials. 2021 Jan 6;22(1):23. doi: 10.1186/s13063-020-04939-2. Trials. 2021. PMID: 33407828 Free PMC article.
-
Randomized clinical trial "olfactory dysfunction after COVID-19: olfactory rehabilitation therapy vs. intervention treatment with Palmitoylethanolamide and Luteolin": preliminary results.Eur Rev Med Pharmacol Sci. 2021 Jun;25(11):4156-4162. doi: 10.26355/eurrev_202106_26059. Eur Rev Med Pharmacol Sci. 2021. PMID: 34156697 Clinical Trial.
-
Medical therapy and smell dysfunction.B-ENT. 2009;5 Suppl 13:71-5. B-ENT. 2009. PMID: 20084807 Review.
-
A primer on viral-associated olfactory loss in the era of COVID-19.Int Forum Allergy Rhinol. 2020 Jul;10(7):814-820. doi: 10.1002/alr.22578. Epub 2020 Jun 1. Int Forum Allergy Rhinol. 2020. PMID: 32271490 Free PMC article. Review.
Cited by
-
Kampo Medicine Promotes Early Recovery From Coronavirus Disease 2019-Related Olfactory Dysfunction: A Retrospective Observational Study.Front Pharmacol. 2022 Mar 30;13:844072. doi: 10.3389/fphar.2022.844072. eCollection 2022. Front Pharmacol. 2022. PMID: 35431935 Free PMC article.
-
Efficacy of Ninjin'yoeito in treating severe coronavirus disease 2019 in patients in an intensive care unit.Neuropeptides. 2021 Dec;90:102201. doi: 10.1016/j.npep.2021.102201. Epub 2021 Oct 1. Neuropeptides. 2021. PMID: 34753072 Free PMC article.
-
Prevention and Recovery of COVID-19 Patients With Kampo Medicine: Review of Case Reports and Ongoing Clinical Trials.Front Pharmacol. 2021 Jun 23;12:656246. doi: 10.3389/fphar.2021.656246. eCollection 2021. Front Pharmacol. 2021. PMID: 34248620 Free PMC article. Review.
-
Prevention, treatment and potential mechanism of herbal medicine for Corona viruses: A review.Bioengineered. 2022 Mar;13(3):5480-5508. doi: 10.1080/21655979.2022.2036521. Bioengineered. 2022. PMID: 35184680 Free PMC article. Review.
-
Multicenter, randomized controlled trial of traditional Japanese medicine, kakkonto with shosaikotokakikyosekko, for mild and moderate coronavirus disease patients.Front Pharmacol. 2022 Nov 9;13:1008946. doi: 10.3389/fphar.2022.1008946. eCollection 2022. Front Pharmacol. 2022. PMID: 36438822 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical